Macromoltek Inc.
Revolutionizing antibody design
Revolutionizing antibody design
Macromoltek Inc. is a biopharma, biotechnology, and pharmaceutical startup that is revolutionizing antibody design. Established in 2010 and headquartered in the United States, the company's slogan "Revolutionizing antibody design" reflects its core mission of utilizing computational modeling to design custom antibodies in just one week. Through their innovative computational approach, Macromoltek Inc. can discover antibodies for a single target, improve existing antibody structures, solve specific antibody design problems, humanize therapeutic antibodies, and map epitopes of antigens. In 22 March 2018, Macromoltek Inc. secured a $120.00K Seed Round investment, with Y Combinator being the investors. This support is indicative of the interest and confidence in the startup and its potential to make significant advancements in the healthcare and biotech industries. With their ability to rapidly and precisely design custom antibodies, Macromoltek Inc. presents a compelling proposition for investors seeking opportunities within the rapidly evolving biopharma and biotechnology sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $120.00K | 1 |
|
22 Mar 2018 |
| Seed Round | Unknown | 2 |
|
01 Jan 2018 |
| Grant | $1.19M | 1 |
|
20 Aug 2016 |
| Grant | $178.70K | 1 |
|
15 Jun 2015 |
No recent news or press coverage available for Macromoltek Inc..
We care about your data, and we'd love to use cookies make your experience better.
